

SLR:slrdm 4/23/04 266079
PATENT

Attorney Reference Number 6235-59216
Application Number 09/857,719

Claim Amendments

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (canceled)

11. (currently amended) A method for treating myocardial pathology, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly to a part of an affected cardiac muscle of a mammal using echocardiographic guidance without thoracotomy, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating myocardial pathology.

12.-13. (canceled)

14. (currently amended) A method for treating myocardial pathology, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly into the cardiac muscle of a mammal, wherein the nucleic acid molecule is administered once a week for 8 weeks, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating myocardial pathology.

15. (canceled)

16. (currently amended) A method for treating a cardiac muscle disorder, comprising administering a nucleic acid molecule encoding a polypeptide effective for the treatment of the disorder into the affected cardiac muscle using echocardiographic guidance without thoracotomy, wherein the polypeptide is HGF that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle and the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome.

17-32. (canceled)

SLR:slr:dm 4/23/04 266079
PATENT

Attorney Reference Number 6235-59216
Application Number 09/857,719

33. (currently amended) A method for treating myocardial pathology, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly into a cardiac muscle of a mammal, wherein administering comprises administering the nucleic acid molecule under echocardiographic guidance without thoracotomy through a catheter, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating myocardial pathology.

34-35. (canceled)

36. (currently amended) A method for treating a disorder, comprising administering a nucleic acid molecule encoding HGF effective for the treatment of a disorder directly into an affected part of a tissue using echocardiography, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the tissue.

37-41. (canceled)